Life Science companies are feeling the pinch; productivity in R&D is dropping, there is increased pressure from regulators as well as pressure on price from payers, not to mention the generics threat. Companies are tightening their belts in terms of cost and ensuring that their current revenue streams are made secure. As the assets of companies in this sector are bound up in intellectual property, it is no surprise that the demand for professionals with IP experience, and in particular patent attorney qualification, is high.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze